We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M Turnover 53.26%
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
+12.32%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$210M
AUM Growth
+$31.7M
Cap. Flow
-$9.22M
Cap. Flow %
-4.38%
Top 10 Hldgs %
41.52%
Holding
75
New
29
Increased
9
Reduced
14
Closed
17
Avg Time Held Equity + Options
0.3 years
Top 10 Avg Time Held Equity + Options
0.4 years
Top 20 Avg Time Held Equity + Options
0.4 years
Avg Time Held Equity only
0.5 years
Top 10 Avg Time Held Equity only
0.6 years
Top 20 Avg Time Held Equity only
0.5 years

Top Buys

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$5.11M
2
AVNS icon
Avanos Medical
AVNS
+$3.8M
3
RVTY icon
Revvity
RVTY
+$3.35M
4
ELGX
Endologix Inc
ELGX
+$2.9M
5
NVRO icon
NEVRO CORP.
NVRO
+$2.66M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$7.56M
2
GSK icon
GSK
GSK
+$6.33M
3
CAH icon
Cardinal Health
CAH
+$4.73M
4
PBYI icon
Puma Biotechnology
PBYI
+$4.48M
5
SNY icon
Sanofi
SNY
+$4.24M

Sector Composition

Rank Sector Weight
1 Healthcare 55.95%
2 Miscellaneous 37.36%
3 Financials 3.75%
4 Industrials 2.24%
5 Technology 0.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
SIOX
51
PUT
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
$689K 0.33%
+3,713
New +$651K
2017 Q2
0 quarters
FOMX
52
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$646K 0.31%
+139,200
New +$621K
2017 Q2
0 quarters
DMK
53
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$637K 0.3%
1,750
-10,862
-86% -$3.25M
2014 Q4
10 quarters
SYRE icon
54
Spyre Therapeutics
SYRE
$7.47B
$499K 0.24%
5,183
-1,613
-24% -$223K
2016 Q2
4 quarters
PFNX
55
DELISTED
Pfenex Inc.
PFNX
$344K 0.16%
85,867
– –
2017 Q1
1 quarter
PHG icon
56
CALL
Philips
PHG
$25.2B
$319K 0.15%
+11,725
New +$307K
2017 Q2
0 quarters
OASM
57
DELISTED
Oasmia Pharmaceutical AB
OASM
$214K 0.1%
203,170
+5,700
+3% +$10K
2015 Q4
6 quarters
VIRX icon
58
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$91K 0.04%
963
-7,949
-89% -$913K
2017 Q1
1 quarter
ALNY icon
59
PUT
Alnylam Pharmaceuticals
ALNY
$31B
– –
-13,500
Closed -$692K –
BIIB icon
60
Biogen
BIIB
$34.4B
– –
-27,650
Closed -$7.56M –
BSX icon
61
Boston Scientific
BSX
$64.3B
– –
-90,000
Closed -$2.24M –
CAH icon
62
Cardinal Health
CAH
$58.8B
– –
-57,950
Closed -$4.73M –
CHRS icon
63
Coherus Oncology
CHRS
$153M
– –
-63,800
Closed -$1.35M –
IQV icon
64
PUT
IQVIA
IQV
$43.9B
– –
-21,500
Closed -$1.73M –
MOH icon
65
CALL
Molina Healthcare
MOH
$10.8B
– –
-50,000
Closed -$2.28M –
MRK icon
66
PUT
Merck
MRK
$360B
– –
-83,840
Closed -$5.08M –
PFE icon
67
PUT
Pfizer
PFE
$169B
– –
-105,400
Closed -$3.42M –
RCKT icon
68
Rocket Pharmaceuticals
RCKT
$239M
– –
-181,725
Closed -$1.45M –
TEVA icon
69
Teva Pharmaceutical Industries Limited
TEVA
$48.4B
– –
-69,500
Closed -$2.23M –
VRTX icon
70
Vertex Pharmaceuticals
VRTX
$127B
– –
-19,475
Closed -$2.13M –
LUMO icon
71
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
– –
-2,824
Closed -$613K –
TMBR
72
DELISTED
Timber Pharmaceuticals, Inc.
TMBR
– –
-21
Closed -$158K –
CERN
73
PUT
DELISTED
Cerner Corp
CERN
– –
-20,000
Closed -$1.18M –
FWP
74
DELISTED
Forward Pharma A/S American Depositary Shares
FWP
– –
-2,032
Closed -$306K –
ANTH
75
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
– –
-41,714
Closed -$142K –
1 2
3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q2 2017 Portfolio in Review

As of Q2 2017, Sio Capital Management held 75 positions worth $210M, up 18% from $179M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sio Capital Management withdrew a net $9.22M in Q2 2017, closing 17 positions and reducing 14 holdings. Its most notable exit was Biogen, an estimated $7.56M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 56% of assets, down from 66% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Sio Capital Management opened a new position in HCA Healthcare worth $5.27M.

  • Sio Capital Management's largest Q2 2017 buy was HCA Healthcare: 60,420 shares worth $5.27M.
  • Sio Capital Management added most to Aetna Inc in Q2 2017, an estimated $2.11M increase.
  • Sio Capital Management's biggest Q2 2017 reduction was GSK, cutting an estimated $6.33M.
  • Sio Capital Management fully exited Biogen in Q2 2017, selling an estimated $7.56M.
  • Sio Capital Management's ten largest holdings make up 42% of its $210M portfolio in Q2 2017.
  • Sio Capital Management opened 29 new positions and closed 17 in Q2 2017.
  • Sio Capital Management's portfolio value rose 18% quarter-over-quarter to $210M.

Based on Sio Capital Management's 13F filing for Q2 2017, filed 14 Aug 2017.